The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.
Roberto Mina, MD
Advertisement
an associate professor at the Winship Cancer Institute of Emory University
Articles by Roberto Mina, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care
2
Semaglutide Shows Promise for Steatohepatitis Resolution in MASH
3
Advancing Biomarker Testing Across GU, Lung, and Myeloma Care
4
Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma
5
